IP Library Granted Patent US 8,658,697
Granted Patent B2
US 8,658,697 · App. 12/925,702 · Granted Feb 25, 2014

Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,658,697
App. No.
12/925,702
Granted
Feb 25, 2014
Kind
B2
Abstract

Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pinchinde, and VSV), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).

Claims (17)

1. A compound selected from the group consisting of:

2-[2,5-bis(2,2,2-trifluoroethoxy)benzoyl]-N-[1,1-bis(trifluoromethyl)propyl]hydrazinecarboxamide;

N-[1,1-bis(trifluoromethyl)propyl]-2-(4-tert-butylbenzoyl)hydrazinecarboxamide;

2-(1,1′-biphenyl-4-ylcarbonyl)-N-[1,1-bis(trifluoromethyl)propyl]hydrazinecarboxamide;

N-[1,1-bis(trifluoromethyl)propyl]-2-(1-naphthoyl)hydrazinecarboxamide;

2-(1,1′-biphenyl-2-ylcarbonyl)-N-[1,1-bis(trifluoromethyl)propyl]hydrazinecarboxamide;

N-[1,1-bis(trifluoromethyl)propyl]-2-(4-methylbenzoyl)hydrazinecarboxamide;

N-[1,1-bis(trifluoromethyl)propyl]-2-(2-naphthoyl)hydrazinecarboxamide;

N-[1,1-bis(trifluoromethyl)propyl]-2-(2,5-dimethoxybenzoyl)hydrazinecarboxamide;

N-[1,1-bis(trifluoromethyl)propyl]-2-(3,4-dichlorobenzoyl)hydrazinecarboxamide;

N-[1,1-bis(trifluoromethyl)propyl]-2-(4-bromobenzoyl)hydrazinecarboxamide;

N-[1,1-bis(trifluoromethyl)propyl]-2-(4-isopropylbenzoyl)hydrazinecarboxamide;

N-[1,1-bis(trifluoromethyl)propyl]-2-(3,5-dimethylbenzoyl)hydrazinecarboxamide;

N-[1,1-bis(trifluoromethyl)propyl]-2-(mesitylcarbonyl)hydrazinecarboxamide; and

N-[1,1-bis(trifluoromethyl)propyl]-2-(5-chloro-2-methoxybenzoyl)hydrazinecarboxamide.

2. The compound of claim 1 , wherein the compound is N-[1,1-bis(trifluoromethyl)propyl]-2-(4-methylbenzoyl)hydrazinecarboxamide.

3. The compound of claim 1 , wherein the compound is N-[1,1-bis(trifluoromethyl)propyl]-2-(2,5-dimethoxybenzoyl)hydrazinecarboxamide.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Apr 2, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
To: SIGA TECHNOLOGIES, INC.
Reel/Frame 035319/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2014
From: SIGA TECHNOLOGIES INC.
To: KINETA FOUR LLC
Reel/Frame 033588/0427 →
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2014
From: GENERAL ELECTRIC CAPITAL CORPORATION
To: SIGA TECHNOLOGIES INC.
Reel/Frame 033544/0324 →
SECURITY AGREEMENT Recorded Dec 31, 2012
From: SIGA TECHNOLOGIES, INC.
To: GE CAPITAL EQUITY INVESTMENTS, INC. C/O GE HEALTHCARE FINANCIAL SERVICES, INC.
Reel/Frame 029557/0771 →